RxDoctor Payments DataLook up a doctor →

Marc Anderson, MD

Family Medicine · Layton, UTNPI 1154307197

Payments from drug & device makers

$2,826,347in general payments, 2019–2025

Across 662 payments — averaging $4269.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2.2M
  • Bavarian Nordic A/s$413K
  • Pfizer$106K
  • Sanofi Pasteur Inc.$76K
  • Sekisui Diagnostics LLC$50K
  • BD$5K
  • plus $13K from 49 others

What the payments were for

  • Travel & lodging$96213%
  • Food & beverage$6,60887%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,826,347 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$193,075
Medicare patients
283
Services billed
14,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$56,502
XareltoRivaroxaban42$48,661
JardianceEmpagliflozin49$41,940
MyrbetriqMirabegron29$29,858
TrulicityDulaglutide20$29,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,172
RybelsusSemaglutide20$26,858
EliquisApixaban39$24,991
MounjaroTirzepatide20$21,897
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,694
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$6,982
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,702
Omeprazole170$3,273
Bupropion XlBupropion Hcl88$3,105
Levothyroxine Sodium258$2,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$79$83,36074 claims
Lilly USA, LLCTrulicity, Mounjaro$625$51,74140 claims
Johnson & JohnsonXarelto$329$48,66142 claims
Boehringer IngelheimJardiance$464$41,94049 claims
Astellas Pharma US IncMyrbetriq$345$29,85829 claims
GSKTrelegy Ellipta$386$29,17235 claims
PfizerEliquis$105,585$24,99139 claims
AstraZenecaBreztri Aerosphere$515$7,69412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →